(Q39518695)

12 September 2017

title

Preparation of the albumin nanoparticle system loaded with both paclitaxel and sorafenib and its evaluation in vitro and in vivo (English)

1 reference

12 September 2017

0 references

1 reference

6

Hua Zhang

1 reference

12 September 2017

Jin-Yang Zhang

1

1 reference

12 September 2017

Bing He

2

1 reference

12 September 2017

Wei Qu

3

1 reference

12 September 2017

Zheng Cui

4

1 reference

12 September 2017

Yi-bo Wang

5

1 reference

12 September 2017

Jian-Cheng Wang

7

1 reference

12 September 2017

Qiang Zhang

8

1 reference

12 September 2017

publication date

27 June 2011

1 reference

Journal of Microencapsulation

12 September 2017

published in

1 reference

12 September 2017

volume

28

1 reference

12 September 2017

issue

6

1 reference

12 September 2017

page(s)

528-536

1 reference

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

Mechanism of hemolysis of red blood cell mediated by ethanol.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

Pharmacogenomics of paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

VEGF and the quest for tumour angiogenesis factors

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

Angiogenesis and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

Computational studies on self-assembled paclitaxel structures: templates for hierarchical block copolymer assemblies and sustained drug release

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

The FMCA-GM assays, high throughput non-clonogenic alternatives to CFU-GM in preclinical hematotoxicity testing

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

Paclitaxel by 1-h infusion in combination with carboplatin in advanced non-small cell lung carcinoma (NSCLC).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

Sorafenib (BAY 43-9006): review of clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

Antiangiogenic strategies and agents in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

Paclitaxel derivatives for targeted therapy of cancer: toward the development of smart taxanes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

Paclitaxel and its formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

Angiogenesis inhibitors: motivators of metastasis?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

Albumin microspheres as carriers for the antiarthritic drug celecoxib.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

Chemotherapy counteracted

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02652048.2011.590614

10.3109/02652048.2011.590614

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference